The Meek Shall Inherit the Pharmacy
New Concept of Hub Signaling May Lead to Specific Targeting
By Anette Breindl
Monday, October 14, 2013
In some ways, the best targets for therapeutic intervention are the worst ones, too – because they are all things to all people. “Many of the key regulators of cell function are signaling hubs,” Alexander Hoffmann told BioWorld Today. And because they are signaling hubs, targeting them pharmacologically is a risky business. NFkB is a prime example. A transcription factor that regulates inflammation when it is activated in response to cytokines and chemokines, NFkB’s levels are elevated in many cancers, and it also plays a role in autoimmune disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.